Eisai, Biogen’s Leqembi Intravenous Infusion cleared for AD treatment in Japan
The Japanese approval was based on Phase 3 results from Eisai’s large, global Clarity AD clinical trial in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Sep 23
The Japanese approval was based on Phase 3 results from Eisai’s large, global Clarity AD clinical trial in…
26 Sep 23
The conditional approval is based on the results from the EPCORE NHL-1 Phase 1/2 trial in which the…
26 Sep 23
The approval was given based on the results from the AReSVi-006 Phase 3 vaccine efficacy trial that enrolled…
26 Sep 23
The acquisition of Decibel builds on prior collaboration between the companies and includes three ongoing gene therapy programs…
25 Sep 23
The approval was based on the data from the EMPA-KIDNEY trial in which Jardiance showed a 28% relative…
25 Sep 23
The EC approval was based on findings from the Phase 2/3 trial conducted in collaboration with the Children’s…
25 Sep 23
First Phase III results in breast cancer for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan
22 Sep 23
The deal will enable Glenmark Pharma to concentrate on its line of branded drugs for the treatment of…
22 Sep 23
The flagship product of Paratek Pharmaceuticals is Nuzyra (omadacycline), an oral and intravenous antibiotic approved for use in…
22 Sep 23
The merged entity will initially focus to advance Cyclo’s Phase 3 global TransportNPC study that is evaluating investigational…